On December 3, 2025, Imexpharm was honored among the Top 20 Best Annual Reports 2025 (Non-Financial Sector) and the Top 10 Best Corporate Governance 2025 (Mid-Cap Group) at the Vietnam Listed Company Awards (VLCA 2025).
.jpg)
Ms. Lê Thanh Hằng (left) – Director of Investor Relations at Imexpharm, representing the company in receiving the commemorative award honoring Imexpharm among the Top 20 Best Annual Reports – Non-Financial Group at the Vietnam Listed Company Awards (VLCA) 2025. Photo: Imexpharm.
The recognition reflects Imexpharm’s years of commitment to enhancing transparency, strengthening governance in line with international standards, and systematically integrating ESG into its long-term development strategy.
VLCA originated from the Vietnam Annual Report Awards and is jointly organized by the Ho Chi Minh City Stock Exchange (HoSE), the Hanoi Stock Exchange (HNX), and Vietnam Investment Review (VIR), with exclusive sponsorship from Dragon Capital Vietnam. VLCA 2025 marks the 18th year the program has accompanied Vietnam’s capital market in elevating disclosure quality and corporate governance practices. Functioning as a “soft benchmark,” VLCA encourages listed companies to continuously improve internal capabilities, upgrade management systems, and advance sustainable business practices.
.jpg)
Ms. Lê Thanh Hằng (left) – Director of Investor Relations at Imexpharm, representing the company in receiving the commemorative award honoring Imexpharm as one of the Top 10 Best Corporate Governance Companies in the mid-cap group at the Vietnam Listed Company Awards (VLCA) 2025. Photo: Imexpharm.
This year’s awards involved nearly six months of preliminary evaluation and independent reviews by the Big Four (Deloitte, Ernst & Young, KPMG, PwC), creating a rigorous selection process for outstanding companies across three pillars: Annual Reporting – Corporate Governance – Sustainability Reporting. Imexpharm’s dual recognition across two of the most critical categories demonstrates the maturity of the 50-year-old pharmaceutical company in transparent governance and effective management.
In the Annual Report category, Imexpharm met strict technical requirements related to disclosure, reporting deadlines, and financial data standardization. Its annual report presents a comprehensive and authentic picture of R&D activities, manufacturing and business performance, and human-capital development strategies.
The report places particular emphasis on CSR and ESG implementation — factors increasingly prioritized by medium- to long-term institutional investors. Imexpharm illustrates how sustainability goals are embedded into core operations, especially through green supply-chain management. This includes adopting a full-cycle “greenization” model across production and procurement, optimizing renewable energy use, reducing greenhouse-gas emissions, investing in wastewater treatment systems that meet ISO 14001 standards, and sourcing CEP-certified raw materials.
A significant contributor to the enhanced reporting quality is Imexpharm’s modernization of its management systems. On January 1, 2025, Imexpharm became the first pharmaceutical company in Vietnam to implement SAP S/4HANA Cloud Private Edition integrated with IFRS. This transformation standardizes data, automates workflows, improves operational efficiency, and strengthens transparency—attributes that align strongly with VLCA’s evaluation criteria for high-quality reporting.
.jpg)
In the Corporate Governance category, Imexpharm stood out for maintaining a governance structure aligned with international best practices, including clear independence between the Board of Directors and the Executive Board, a reinforced internal-control and risk-management framework, strong shareholder-rights protection, and consistent, timely disclosure of essential information. Imexpharm applies the ASEAN Corporate Governance Scorecard and operates a comprehensive Enterprise Risk Management (ERM) model to identify and manage strategic, operational, financial, and environmental risks, ensuring business continuity.
Imexpharm is also included in the VNSI20 Sustainability Index, underscoring the company’s not only compliance but active implementation of ESG throughout its operations. These strengths positioned Imexpharm among the Top 10 best-governed mid-cap companies at VLCA 2025.
.jpg)
Alongside its governance enhancements, transparency initiatives, and ESG-driven orientation, Imexpharm continues to expand its world-class manufacturing capabilities. The company currently leads Vietnam’s pharmaceutical industry with 12 EU-GMP production lines across three EU-GMP manufacturing clusters, and holds 28 European Marketing Authorizations (EU-MAs) for 11 products. These capabilities are reflected not only in national rankings and awards but also in the company’s strong business performance.
For the first 10 months of 2025, Imexpharm recorded revenue of VND 2,011 billion, up 16% year-on-year, and profit before tax of VND 361 billion, an increase of 23% compared to the same period last year. With steady revenue growth and optimized cost efficiency, the company has fulfilled 80% of its gross revenue target, 76% of net revenue, and 73% of its pre-tax profit and EBITDA plan for the year